Precemtabart Tocentecan

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of precemtabart, a human immunoglobulin G1-kappa monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA), conjugated with tocentecan, which consists of a linker and the cytotoxic agent and camptothecin analog exatecan, with potential antineoplastic activity. Upon administration of precemtabart tocentecan, the precemtabart moiety targets and binds to CEACAM5 expressed on tumor cells. Upon binding and internalization, exatecan is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in CEACAM5-expressing tumor cells. CEACAM5, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types.

**Synonyms:** - Anti-CEA ADC M9140 - Anti-CEA Antibody-drug Conjugate M9140 - Anti-CEACAM5 ADC M9140 - Anti-CEACAM5 Antibody-drug Conjugate M9140 - M 9140 - M-9140 - M9140 - PRECEMTABART TOCENTECAN